Back to Journals » OncoTargets and Therapy » Volume 10

Overexpression of ecotropic viral integration site-1 is a prognostic factor of lung squamous cell cancer

Authors Xu X, Liu S, Ji X

Received 14 January 2017

Accepted for publication 17 March 2017

Published 26 May 2017 Volume 2017:10 Pages 2739—2744

DOI https://doi.org/10.2147/OTT.S132410

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr William Cho

Xueliang Xu,1 Shengchen Liu,2 Xia Ji1

1Department of Respiratory Medicine, 2Department of Emergency, Linyi People’s Hospital, Linyi, China

Aim: To explore the expression and clinical significance of ecotropic viral integration site-1 (EVI1) of lung squamous cell cancer (SCC).
Methods: The expression of EVI1 in SCC was detected by immunohistochemistry and the validation cohort was divided into EVI1 high-expression group and low-expression group according to the cutoff of immunohistochemical score. The correlations between EVI1 expression and the clinicopathological factors were analyzed by χ2 test. The relation between EVI1 expression and overall survival rate was evaluated by univariate analysis with Kaplan–Meier method. The independent prognostic factor was identified by multivariate analysis with Cox regression model.
Results: In this study, the EVI1 high-expression percentage was 32.32% (53/164). EVI1 high expression was significantly associated with a poorer overall 5-year survival rate of SCC (P=0.021). Moreover, EVI1 high expression was identified as an independent prognostic factor of SCC, predicting the unfavorable prognosis (P=0.013).
Conclusion: High expression of EVI1 was significantly associated with a poorer prognosis and it was identified as an independent prognostic factor of SCC.

Keywords: ecotropic viral integration site-1, lung squamous cell cancer, biomarker, prognosis, immunohistochemistry, overall survival rate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]